This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.
Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Buenos Aires, Argentina
Buenos Aires, Argentina